Ovotransferrin Supplementation Improves the Iron Absorption: An In Vitro Gastro‐Intestinal Model

Bioseutica® Ovotransferrin

Comparative Analysis of Ovotransferrin and Lactoferrin: Iron Transport and Bioactive Properties in Human Health"

Ovotransferrin, a protein abundant in hen egg white, shares many activities as human/bovine lactoferrin. Ovotransferrin combines iron transport and the defense functions of mammalian serum transferrin and lactoferrin,  respectively. It also shares approximately 50% of the sequence homology with each  protein. However, the structural analogy between ovotransferrin and lactoferrin is much closer than the sequence homology and similar clusters of positively charged residues responsible for different activities such as antiviral/bacterial, immunomodulatory,  antioxidant, and anti‐inflammatory properties. In addition, this protein has been demonstrated to supply iron to cells. Ovotransferrin is readily digested by pepsin in the stomach, and the bioactive forms of ovotransferrin are readily transported into human intestinal cells. Despite a large body of evidence that supports the beneficial impact of various lactoferrin preparations on human health, there is still very little information regarding the mode of action of lactoferrin and whether saturation of the protein with Fe affects its function and also similarly observed with ovotransferrin. Given this premise, in this study, we analyzed the release, absorption, and biological activity of ovotransferrin from hen egg white with a different iron saturation rate and bovine lactoferrin using a well-characterized in vitro model of the digestive system mimicking the human gastro‐intestinal system both in the presence or absence of Fe3+. The findings obtained in this study demonstrate that holo‐OvT was able to maintain a higher significant beneficial effect on cell viability and integrity compared to the other holo‐OvT  and bLact tested in both gastric and intestinal compartments, confirming the important  hypothesis of the iron saturation rate to obtain beneficial effects.

Bioseutica® B.V, The Netherlands, partially sponsored the study. In addition, this study was (partially) funded by the Italian Ministry of Education, University and Research (MIUR) program “Departments of Excellence 2018– 2022”, AGING Project–Department of Translational Medicine, Università del Piemonte Orientale.